We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.
Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.
Help shape the future of healthcare benefits by sharing your insights.
In an interview, Sheppard Mullin Partner Michael Orlando highlighted some potential pitfalls from contract negotiations to pilot study design and what startups can do to navigate them to strengthen their business.
As virtual rehabilitation picks up, traditional orthopedics widget makers like Breg are foraying into at-home physical therapy using a sensor device and a companion mobile app.